Evidence map›Paper›PMID 40762580›Full record

ReviewFuture medicinal chemistry2025

Small-molecule Cathepsin K inhibitors: a medicinal chemistry perspective.

Xuan Guan, Shu Cheng, Yifei Yin, Shufang Du

Abstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in Future medicinal chemistry, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors.

Xuan GuanState Key Laboratory of Oral Diseases, West China School of Stomatology, National Clinical Research Center for Oral Diseases, Sichuan University, Chengdu, China.
Shu ChengState Key Laboratory of Oral Diseases, West China School of Stomatology, National Clinical Research Center for Oral Diseases, Sichuan University, Chengdu, China.
Yifei YinState Key Laboratory of Oral Diseases, West China School of Stomatology, National Clinical Research Center for Oral Diseases, Sichuan University, Chengdu, China.
Shufang DuState Key Laboratory of Oral Diseases, West China School of Stomatology, National Clinical Research Center for Oral Diseases, Sichuan University, Chengdu, China.ORCID 0009-0001-9498-4826

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Cathepsin K (Cat K) is a member of the Cathepsin family and is found in a wide range of tissues. Cat K is involved in the terminal catabolism and recycling of endocytosed proteins, as well as specific cellular processes and a wide range of diseases. It is predominantly expressed in osteoclasts and has potent collagenase activity. Based on its particular structure and biological functions, Cat K inhibitors with precise targeting and good penetration are potential therapeutic approaches for related diseases. In this paper, we introduce the structure and biological functions of Cat K and focus on Cat K inhibitors with therapeutic potential for human diseases.

Indexed as

Cathepsin KCysteine Proteinase InhibitorsSmall Molecule LibrariesAnimalsChemistry, PharmaceuticalHumansCathepsin KCTSK protein, humanCysteine Proteinase InhibitorsSmall Molecule LibrariesCathepsin Kdrug designmolecular binding modessmall molecule inhibitorsstructure-activity relationships (SAR)

Identifiers

PMID40762580
PMCPMC12506716

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.